Three months after President Donald Trump announced his blueprint to bring down drug prices, administration officials have begun putting some teeth behind the rhetoric.
Access to powerful new cholesterol-lowering drugs is so tightly controlled and patients’ out-of-pocket costs are so high that fewer than a third of people whose doctors prescribe the drugs get them, a new study found.
Before Luke Whitbeck began taking a $300,000-a-year drug, the 2-year-old’s health was inexplicably failing.
A pale boy with enormous eyes, Luke frequently ran high fevers, tired easily and was skinny all over, except his belly stuck out like a bowling ball.
The 2010 health law was meant to expand insurance coverage so that Americans could get medical care they would otherwise go without — and not spend a fortune doing so. Though it’s still early, new evidence suggests this scenario is playing out.
Like a clump of Scotch broom sprouting each year on Oregon hillsides no matter how many times it gets pulled, the pharmaceutical companies are repeating their efforts from past sessions to restrict the ability of pharmacists to dispense generic or “biosimilar” alternatives to so-called biological
BERLIN – June 28, 2012 -- Now that the Supreme Court has upheld President Obama’s healthcare plan, pharmaceutical companies, patients and healthcare experts in Europe are waiting to see how a new cost reducing drug price mechanism affects them.
Requiring citizens to have healthcare has long been a staple of European health insurance programs. But now governments and insurers are trying to stem the cost of exorbitantly expensive new drugs.